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NASA STI Program . . . in Profile
Since its founding, NASA has been dedicated to the
advancement of aeronautics and space science. The
NASA Scientific and Technical Information (STI)
program plays a key part in helping NASA maintain
this important role.
The NASA STI Program operates under the auspices
of the Agency Chief Information Officer. It collects,
organizes, provides for archiving, and disseminates
NASA’s STI. The NASA STI program provides access
to the NASA Aeronautics and Space Database and
its public interface, the NASA Technical Reports
Server, thus providing one of the largest collections
of aeronautical and space science STI in the world.
Results are published in both non-NASA channels
and by NASA in the NASA STI Report Series, which
includes the following report types:
TECHNICAL PUBLICATION. Reports of
completed research or a major significant phase
of research that present the results of NASA
programs and include extensive data or theoretical
analysis. Includes compilations of significant
scientific and technical data and information
deemed to be of continuing reference value.
NASA counterpart of peer-reviewed formal
professional papers but has less stringent
limitations on manuscript length and extent of
graphic presentations.
• TECHNICAL MEMORANDUM. Scientific
and technical findings that are preliminary or
of specialized interest, e.g., quick release
reports, working papers, and bibliographies that
contain minimal annotation. Does not contain
extensive analysis.
• CONTRACTOR REPORT. Scientific and
technical findings by NASA-sponsored
contractors and grantees.
• CONFERENCE PUBLICATION. Collected
papers from scientific and technical
conferences, symposia, seminars, or other
meetings sponsored or cosponsored by NASA.
• SPECIAL PUBLICATION. Scientific,
technical, or historical information from
NASA programs, projects, and missions, often
concerned with subjects having substantial
public interest.
• TECHNICAL TRANSLATION. English-
language translations of foreign scientific and
technical material pertinent to NASA’s mission.
Specialized services also include creating custom
thesauri, building customized databases, organizing
and publishing research results.
For more information about the NASA STI
program, see the following:
• Access the NASA STI program home page at
http://www.sti.nasa.gov
• E-mail your question via the Internet to help@
sti.nasa.gov
• Fax your question to the NASA STI Help Desk
at 301–621–0134
• Telephone the NASA STI Help Desk at
301–621–0390
• Write to:
NASA Center for AeroSpace Information (CASI)
7115 Standard Drive
Hanover, MD 21076–1320
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Vision and Plan
The John Glenn Biomedical Engineering Consortium was established by NASA in 2002 to formulate
and implement an integrated, interdisciplinary research program to address risks faced by astronauts
during long-duration space missions.
The consortium is comprised of a preeminent team of Northeast Ohio institutions that includes the
following
(1) Case Western Reserve University (CWRU)—offers a Biomedical Engineering Program that is
one of the top programs in the nation. MetroHealth Medical Center in Cleveland is part of the consortium
through its affiliation with the CWRU School of Medicine.
(2) The Cleveland Clinic—excels as one of the top hospitals in the nation and has ranked number one
in cardiac care in the U.S. for the past 14 years. The Clinic’s Lerner Research Institute provides
laboratory-based, translational and clinical research aimed at understanding the underlying causes of
human diseases and developing new treatments and cures.
(3) University Hospitals Case Medical Center (UHCMC)—ranks nationally in numerous specialties
with a rich history filled with medical innovation, leading-edge research, teaching, and a bedrock
commitment to outstanding patient care.
(4) The National Center for Space Exploration Research (NCSER)—demonstrates superior
capabilities in fluid physics, computational simulation, and instrumentation.
(5) NASA’s Glenn Research Center (GRC)—has outstanding competency in interdisciplinary
bioengineering for human systems along with exceptional spaceflight hardware development, sensors,
diagnostics and computational modeling expertise.
The John Glenn Biomedical Engineering Consortium research is focused on fluid physics and sensor
technology that addresses the critical risks to crew health, safety, and performance. Effectively utilizing
the unique skills, capabilities and facilities of the consortium members is also of prime importance.
Research efforts were initiated with a general call for proposals to the consortium members. The top
proposals were selected for funding through a rigorous, peer review process. The review included
participation from NASA’s Johnson Space Center, which has programmatic responsibility for NASA’s
Human Research Program. Almost all of the projects initially selected involved collaboration among the
consortium institutions, which ensured that the very best capabilities of the members were utilized in
conducting the research. A board was established with senior executive membership from each
institution. The board assures that the appropriate resources and capabilities of all members are utilized to
achieve the goals of the consortium. The board also fosters a cooperative relationship between all member
institutions. All of the projects selected for funding have been completed. Because of the success of the
consortium, the member institutions have extended the original agreement to continue this highly
effective research collaboration through 2011.
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The Projects
The projects range in scope from delivery of prototype hardware to applied research that enables
future development of advanced technology devices. Highlights of the completed projects are given
below. They are discussed as one of two current Human Research Program areas of emphasis: Exercise
Countermeasures and Exploration Medical Capability. Exercise Countermeasures provides requirements
for optimized and validated exercise protocols and equipment that maximize benefits to the body,
minimize crew time required for exercise, and minimize volume and mass requirements for exercise
hardware. Exploration Medical Capability develops requirements and advanced technologies for clinical
medical systems requiring little or no real-time support from Earth and a probabilistic analysis model of
health care delivery during exploration missions.
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Exercise Countermeasures
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Exercise Prescription Monitoring and Feedback for
Bone Mass Maintenance
Principal Investigator: Gail P. Perusek, M.S., GRC
Co-Investigators: Brad Humphreys, Ph.D., ZIN Technologies, Inc.
Marcus Just, Ph.D., ZIN Technologies, Inc.
Carlos Grodsinski, Ph.D., ZIN Technologies, Inc.
Peter R. Cavanaugh, Ph.D., D.Sc., Cleveland Clinic
	
In space, astronauts exercise to counteract the detrimental 	 ^^ r^^^,	 n
	physiological effects of spaceflight, including bone loss. The	 •^^
skeletal system adapts to mechanical loading by the “adaptive
remodeling response.” When mechanical loading is diminished
•.(e.g., in magnitude, rate, duration), as during spaceflight,
	
significant bone loss is observed in weight-bearing skeletal 	 ' )^	 g	 g	 /
	locations. Astronaut exercise prescriptions do not currently employ	 • ,
biometrics for quantifying accumulated mechanical loads in space,
nor are astronauts monitored to evaluate actual versus prescribed
dosage. The objective of this project was to develop a monitoring
algorithm based on the daily load stimulus (DLS) theory of bone
mass maintenance and implement this algorithm on biometric Figure 1.—The enhanced Zero-Gravity Locomotion Simulator
	monitoring hardware to actively measure DLS dosage based on 	 (eZLS) at NASA Glenn.
vertical ground reaction force and provide feedback to the test
subject in real time. Results were demonstrated on the enhanced Zero-gravity Locomotion Simulator at
NASA Glenn, which included supplying real-time feedback to the exercising subject. The DLS dosage
interface was analogous to “filling a bucket.” Progress was displayed on a computer screen indicating
when the accumulated dosage was reached. The project resulted in significant advancement of a highly
practical monitoring algorithm for prescribing daily load stimulus through quantifying foot reaction force.
Using this approach, exercise sessions can be optimized and overall bone loss may be reduced. This
project leveraged funding and resources from the other research projects funded through the National
Space Biomedical Research Institute (NSBRI), a Small Business Innovative Research (SBIR) Phase 1
effort, and a flight experiment activity. The results may be applied to health care on Earth such as
physical activity monitoring and osteoporosis prevention.
NASA/TM—2009-215592 	 4
A Harness for Use With Exercise Countermeasures
Principal Investigator: Peter R. Cavanagh, Ph.D., D.Sc., Cleveland Clinic
Co-Investigators: Gail Perusek, M.S., GRC
Carlos Grodsinski, Ph.D., ZIN Technologies, Inc.
Treadmill exercise has been used on orbit since early
space shuttle flights because it has the potential to
simultaneously benefit the neurovestibular, musculoskeletal,
and cardiovascular systems. Extensive effort has been put 	 \	 p'"
forth toward the development of exercise countermeasures, yet
bone continues to be lost on current International Space 	 r'3 	 ^_
Station (ISS) missions and is a major concern for future	 y`k'
^ • 	 tit.	 _.,,:
exploration missions. A treadmill with vibration isolation 	 r,••	 ;^ y; n "'..	 ' .r .;^
1 .^	
.. rr..+^ r '(TVIS) has been a major component of the exercise hardware 	 ^'	 •=
on the ISS. However, it has not proven to be a successful
countermeasure. The key to the success of load-bearing 	 a	 ! '	 •;
exercise ins ace such as treadmill running, the application f:'	 r'Ep	 g,	 pp ^	 ^	 I
of loads to the crew member via a subject load device coupled
to the body by a harness. ISS crew members frequently report
discomfort from the current types of exercise harnesses, which
makes the exercise protocols less effective. Experiments on the 	 Figure 2.—Prototype harness developedISS have shown that this has resulted in low ground reaction 	 under the John Glenn Biomedical
forces on orbit (approximately 60 percent of 1 g loads), which 	 Engineering Consortium.
is likely to be a major factor in the observed loss of bone
mineral density in crew members. This project utilized valuable insights from the backpack industry for
harness configuration and distributing loads to develop an improved harness. Based on preliminary
consultation with industry experts, the harness was designed to minimize vertebral column loading. Form-
fitting thermoplastic to mold the waist belt was used to better distribute loads to accommodate for
individual differences, including gender. The project resulted in the advancement of a new, more
comfortable harness design that is now being developed for flight testing on the ISS. Sensors to measure
load distribution were developed during pilot testing of the prototype harness. This load sensing
methodology will be used during the flight experiment to obtain comparisons of load and comfort
between the new harness and the current U.S. ISS harness.
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Development of a “Recompression Chamber” to Prevent Bone Loss
in Space Through Exogenous Application of Acoustic Energy
Principal Investigator: Ulf Knothe, M.D., D.Sc., Cleveland Clinic
Co-Investigators: Dwight Davey, Ph.D., CWRU
Melissa Knothe Tate, Ph.D., CWRU
Developing countermeasures to prevent bone loss due to exposure to microgravity is a high priority in
reducing risk for human space flight. The objective of this project was to develop and optimize a
countermeasure for prevention of bone loss in microgravity based on exogenous application of acoustic
energy. The first phase of the project identified the bandwidth and application regime necessary to
enhance fluid flow and mass transport through the bone matrix and produce low-level diffuse
microdamage in the bone matrix. This was done first in ovine bone samples and then in an ex vivo rat
model. The ex vivo study showed the efficacy of the energy regime to produce low-level, diffuse
microdamage in bone, mimicking that which occurs naturally through physiologic activity. In the second
phase, the same energy regime was applied to rats in vivo and the rats were allowed to recover over a
four-week period. This in vivo study showed that lithotripsy triggered a remodeling response in addition
to significant bone apposition compared to untreated groups. In the final phase of the project, osteopenic,
middle-aged rats were exposed to lithotripsy to evaluate the effectiveness of acoustic shock waves in
counteracting bone loss due to simulated microgravity. Results showed, for the first time, that lithotripsy
stimulates bone apposition and is a potential therapy to prevent bone loss associated with exposure to
microgravity. This technique could also be used to prevent bone loss on Earth due to inactivity. This
project effectively leveraged funds and equipment from other projects. Interest has been shown in
exploring a commercial application of lithotripsy to prevent and combat osteopenia.
Figure 3.—Microdamage throughout the cortex of the cross section resulting
from the application of acoustic energy to cortical bone blocks.
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Two-Photon Microscopy for the Assessment of Countermeasures
in Bone Loss
Principal Investigator: Greg A. Zimmerli, PhD., GRC
Co-Investigators: David G. Fischer, Ph.D., GRC
Marius Asipauskas, Ph.D., NCSER
Melissa L. Knothe Tate, Ph.D., CWRU
Bone loss in weight-bearing skeletal locations during long-
duration spaceflight is a serious issue for astronauts. Data from
NASA’s crewed missions indicates that astronauts experience
a significant reduction in bone mass density (BMD) due to
exposure to microgravity. It is also of concern for long stays
under partial gravity conditions such as on the surface of the
Moon and Mars. Analysis suggests that the weight-bearing
bones of an astronaut returning from a 30-month mission to
Mars could have the equivalent BMD of an 80-year-old
person. Because of its dense, optically opaque structure, bone
tissue is a particularly challenging subject for white light
imaging or fluorescence microscopy. This project investigated
the quality of bone imaging provided by two-photon
fluorescence microscopy compared to traditional confocal
fluorescence imaging. Fresh frozen human femur and tibia
samples were prepared and imaged using a custom-built two- 	 Figure 4.—Image gallery of spectrally
photon microscope and a confocal microscope. The two-photon	 resolved, false color, two-photon image
in technique showed distinct advantages including better 	 of bone tissue stained with basicimag gg	 q	 g	 g	 fuchsin.
signal and contrast when imaging 50 percent deeper into the
bone tissue, a significantly better penetration depth, and advantageous spectral resolution characteristics
compared to traditional confocal imaging techniques. This project demonstrated the benefit of using two-
photon microscopy to understand the underlying mechanisms of bone changes by studying cellular
activity in a living animal, in real time. In addition, the project conducted research to better understand in-
vitro bone cell cultures and the regulation of expressed proteins. In particular, the gene regulation effect
that fluid flow has on osteoblasts was examined.
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Portable Unit for Metabolic Analysis (PUMA)
Principal Investigator: Daniel L. Dietrich, Ph.D., GRC
Co-Investigators: Nancy D. Piltch, Ph.D., GRC
Marco E. Cabrera, Ph.D., CWRU
Peter M. Struk, Ph.D., NCSER
Richard D. Pettegrew, Ph.D., NCSER
It is critical to keep astronauts safe, healthy and
physically fit during long-duration missions.
Metabolic monitoring of astronauts can provide
essential data during activities including exercise
and extravehicular activity (EVA). However,
stringent requirements for accuracy, weight,
volume and portability pose significant challenges
for devices needed to provide the essential
metabolic data. The Portable Unit for Metabolic
Analysis (PUMA) Project developed an innovative
device that measures the six key quantities
(oxygen, carbon dioxide, flow, temperature,
pressure, and heart rate) needed to evaluate human
metabolic function. PUMA is a battery-powered,
self-contained device capable of measuring
metabolic function at rest, during exercise, in
clinical settings, or in the field. The device
	
Figure 5.—PUMA headgear.
transmits data wirelessly to a laptop computer. It offers significant advantages over currently available
portable units including superior measurement technology and highly time-resolved measurements of all
relevant quantities, which eliminates the timing issues present in other devices. The integration of gas
concentration profiles to obtain breath-by-breath analysis provides more accurate information than the
single concentration per breath measurement obtained by other units. Also, the placement of essential
sensors is closer to the mouth than other units. PUMA uses superior oxygen sensor technology with faster
response, negligible drift, and no sensitivity to carbon dioxide (compared to currently available portable
units). The project developed and evaluated three generations of the PUMA unit incorporating
improvements from generation to generation. Human subject testing was conducted through a series of
tests at the exercise physiology laboratories located at UHCMC and at NASA Johnson. PUMA has also
been tested in the NASA Extreme Environment Mission Operations (NEEMO) underwater Aquarius
habitat. NASA has applied for a patent for the PUMA device. Numerous opportunities exist for
application to improve health care on Earth where basic physiological measurements are required
including occupational fitness evaluations and training as well as dietary, nutrition, weight loss, and
exercise studies.
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A MicroSensor Array for Exercise and Health Monitoring
Principal Investigator: Gary W. Hunter, Ph.D., GRC
Co-Investigators: Daniel M. Laskowski, Ph.D., RPFT/CCRC
Raed A. Dweik, M.D., Cleveland Clinic
Chung-Chiun Liu, Ph.D., CWRU
Joseph R. Stetter, Ph.D., Transducer Technology, Inc.
Darby B. Makel, Ph.D., Makel Eng., Inc.
Benjamin J. Ward, Ph.D. Makel Eng., Inc.
The objective of this project was to develop a 	 ::-•^ti•^ "'--	 ""—;--' °'-•^"^
o^Dninnsor M .mii"'U	 fNfig/Sanminiaturized metabolic gas monitor system for use in	 Se 	 ' • •	 _
YL
astronaut feedback during exercise and in astronaut ' • _	 •^' .
health monitoring. The results contribute to reducing •	 2
astronaut health risks in areas such as diminished 	 ••	 •'
cardiac and vascular function and reduced muscle mass, 	 :; •	 ,••
strength and endurance. The project team fabricated, 	 ••	 :^	 ._	 • A'
IMMtested, and delivered an integrated breath-monitoring I
sensor system that included an array of gas 	 • 
1
I"	 ••
microsensors, a data acquisition and display unit, a ^•'	 °_	 ^••	 _ _____	 _	 Y
sample pump, and a mouthpiece. The core species I	 -	 • .	 ' '• it —	 -y	 7• r,P ,.
1	 SantpLe P^mtpJ, •	 .	 4
monitored were carbon dioxide and oxygen along with 	 ..
other species including carbon monoxide, nitrogen 	 ' , '	 Y	 • .	 •...
oxides (NO, NO2), hydrogen sulfide, pH, and	 Figure 6.—Breath sensor system.
temperature. Team members at Makel Engineering Inc.
and the Cleveland Clinic completed significant miniaturization of the testing system and performed
complete system characterization, including patient testing. Testing demonstrated that high temperature
oxygen and carbon dioxide sensors provide the functionality required for a breath monitoring system. The
results outline a system for exercise feedback and personal health monitoring for use on Earth or in space.
The type of sensor system developed through this project may be used in the future as a replacement for
the traditional lab rack-sized equipment currently used. The collaboration established through this project
led to a recent State of Ohio Third Frontier Award to develop a breath sensor system (starting with
nitrogen oxide measurements) for home health applications that focus on asthma patients. This involves
the Cleveland Clinic, Makel Engineering, The Ohio State University, and CWRU.
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Exploration Medical Capability
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Project “Rescue” for Diagnosis and Treatment
of Cardiac Dysrhythmia
Principal Investigator: David W. York, GRC
Co-Investigator: David S. Rosenbaum, M.D., CWRU, MetroHealth System
Chief Engineer: Michael A. Mackin, GRC
Serious cardiac rhythm disturbances have been
recorded on several occasions during spaceflight. Cardiac
dysrhythmia may pose a risk during long-duration
spaceflight and is therefore being addressed by NASA’s
Human Research Program. Project “Rescue” developed a
system of prototype hardware and software to aid in the
detection and diagnoses of serious cardiac dysrhythmia.
The system includes the ability to capture and display near
real-time electrocardiogram (ECG) data locally (e.g., on
board a spacecraft) and remotely (e.g., on Earth) using
Embedded Web Technology (EWT). The system provides
detection and diagnostic information using EWT, which
was first developed at NASA Glenn for other applications.
A team from MetroHealth worked with NASA personnel
to establish appropriate protocols and research objectives
for the measurement of T-wave alternans and ECG
Figure 7.—Researchers will test this prototype
of the heart monitoring system for
ambulatory patients with arrhythmia
symptoms.parameters, which are potential indicators for susceptibility
to ventricular fibrillations and other potentially life-threatening arrhythmias. MetroHealth also provided
the services of nurses with specialized training in T-wave measurements to prepare test subjects and
ground baseline data acquisition for a series of microgravity flight tests in the KC-135 research aircraft.
Analysis of the test data by MetroHealth confirmed that the T-wave alternans test provides accurate data
during microgravity flight. Based on project success, clinical trials of the technology were initiated by
MetroHealth. A potential commercial partner has expressed interest in the system, pending the outcome
of clinical trials. NASA and MetroHealth have applied for a patent on the technology. Components of
Project “Rescue” can also be used with other projects, such as PUMA, to collect, transmit, manipulate and
store data.
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A Dual-Track Actuated Treadmill in a Virtual Reality
Environment: A Countermeasure for Neurovestibular
Adaptation in Microgravity
Principal Investigators: Susan E. D’Andrea, Ph.D.
Brian Davis, Ph.D., Cleveland Clinic
Co-Investigator: Jay G. Horowitz, Ph.D., GRC
The neurovestibular system is primarily responsible for
balance and stabilization. The microgravity environment 	 Od,
alters the cues given to the human neurovestibular system,	 '
resulting in sensory conflicts during reentry and post flight.
This can cause crew members to suffer from disabling 	 r	 '`I^^.	 rar
vertigo, oscillopsia, sudden loss of orientation, and overall 	 --^
decreased ability in standing and performance.
Countermeasures are needed to eliminate these effects and
assure crew safety and performance. A sophisticated dual-
track  treadmill was developed and utilized in conjunction
with a virtual reality environment to potentially mitigate these
deleterious effects. Extensive instrumentation was utilized in 	 t:
rigorous biomechanical testing that involved 24 human 	 ]	 ,.,.
subjects. It was found that by increasing the input stimulus to 	 '`'	 s
the body (specifically, movements of the head), the treadmill 	 +=	 `
forces the user to consistently activate his/her balance 	 r
reflexes. Test results demonstrated the potential for the dual- 	 Figure 8.—Subject on Dual Track
track, actuated treadmill device with virtual reality to help 	 Treadmill with Virtual Reality.
alleviate the postural and balance disturbances after exposure
to microgravity. In addition to utilization for NASA’s
exploration missions, this instrumented treadmill could be an effective tool for rehabilitating patients on
Earth suffering from balance disorder or other problems involving the neurovestibular system.
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Figure 9.—Space goggles concept for
monitoring astronaut health.
Integrating Noninvasive Technologies to Enable Effective
Countermeasures During Prolonged Space Travel
Principal Investigator: Rafat R. Ansari, Ph.D., GRC
Co-Investigator: Marco E. Cabrera, Ph.D., CWRU
Effective monitoring of astronaut health and the early
detection of potential issues are critical for long-duration
space missions. This project investigated the development
of optical sensors for noninvasive, quantitative medical
evaluations of the eyes, skin, and brain. These sensors
could ultimately be integrated into a head-mounted device
for monitoring and evaluating astronaut health, similar to a
pair of goggles. The device would be equipped with a suite
of optical biosensors for noninvasive and quantitative
medical evaluations. Efforts included continuing work on a
new technology for the early detection of cataracts that was
developed and validated for clinical use at the National
Institutes of Health (NIH). This technology is being used in
clinical trials of anticataract drugs that have the potential of
being used by people on Earth as well as by astronauts. A
noninvasive sensor for glucose monitoring through the eye was developed with the potential for
management of diabetes and other systemic diseases on the ground. A laser-Doppler flowmeter for
measuring blood flow in the eye to address changing hemodynamic conditions under reduced gravity was
developed and tested under low gravity conditions in the KC-135 aircraft. It has been adapted for
measuring blood flow in distal finger tips to study the causes of injury to an astronaut’s fingers during
extravehicular activity. The project included the evaluation of existing technology (near-infrared
spectroscopy) and its potential application in exercise-related studies for astronauts and children. The
technology may also be applied for use in the intensive care unit. Because of the successes achieved,
these efforts will now move to the clinical domain at the University of Texas/Texas Medical Center in
Houston.
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Sliver Sensor: A Microminiature Monitor for Vital Electrolyte and
Metabolite Levels With Adaptability, Self-Checking Capability, and
Negligible Power Requirements
Principal Investigator: Miklos Gratzl, Ph.D., CWRU
Co-Investigator: Koji Tohda, Ph.D., CWRU
Understanding changes in human physiology during space missions is important to maintaining
astronaut health and safety. The Sliver Sensor is a novel device that was conceived, developed and tested
for in vivo monitoring of glucose and electrolytes in the interstitial fluid of astronauts during spaceflight.
In addition to increasing basic understanding of metabolic changes in space, the device could also be
critical in identifying and handling certain medical emergencies. The minimally invasive, micro miniature
Sliver Sensor is placed just under the skin. Individual optical sensing capsules in the device change color
with changes in concentration of glucose and basic electrolytes. The changes in color are read by an
external watch-like device. The optical coupling eliminates the need for wires or optical fibers crossing
the skin. In vivo biocompatibility studies on rats were conducted and the sensors were found to be
biocompatible for at least 28 days. On Earth, the device can be used to monitor electrolytes in the blood
of critically ill patients and for diabetes management. An industry sponsored project enhanced the
research conducted under this project. An award was received from the Coulter-Case Translational
Research Partnership for complete in-vivo testing of the developed device. Pre-clinical trials are expected
to occur in the near term.
Figure 10. —An optical glucose, pH and K+ sensor together
with optical white reference.
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A High-Resolution Portable Ultrasonic Imaging System
Principal Investigator: Shuvo Roy, Ph.D., Cleveland Clinic
Co-Investigators: Aaron Fleischman, Ph.D., Cleveland Clinic
Noel Nemeth, Ph.D., GRC
Ken Goldman, Ph.D., H-Cubed, Inc.
Developing small ultrasonic imaging systems is
important to diagnose skin and bone problems in
space because other imaging technologies are not
compatible with spaceflight. The objective of this
project was to develop a portable, high-resolution
ultrasonic imaging system for accurate diagnosis and
monitoring of skin and bone conditions of astronauts.
Specific bone conditions of interest included bone loss
and fracture detection. A system was developed using
4 mm-diameter polyvinylidene fluoride (PVDF)
focused ultrasonic microtransducers. Prototypical
transducers had a 40 MHz center frequency with a Figure 11.—Volume renderings of the ultrasound
fractional bandwidth of 60 percent. High-resolution	 three-dimensional image.
imaging of human cancellous bone was successfully demonstrated using a bone specimen excised from a
cadaveric human calcaneus. The bone was scanned in increments of 0.1 mm using a high-precision
motorized stage. Amplitude of the received signal was detected along the scan lines and converted into
image density. Then, regular visualization methods applied. Ray casting with blending was used for three-
dimensional (3–D) volume rendering. This project demonstrated that high-frequency focused ultrasonic
microtransducers can be used to image bone in both fundamental and harmonic imaging modes. Overall,
the technical accomplishments have established the feasibility of ultrasound imaging for examining bone
microstructure. With additional development, the PVDF microtransducers can be integrated into a
portable ultrasound imaging system, which can applied to the diagnosis of fractures and bone loss in
astronauts on space missions. On Earth, the availability of portable ultrasound systems can enhance
clinical diagnosis for application in remote telemedicine, which is currently encumbered by expensive and
bulky equipment. The focused ultrasonic transducer has also been used to examine coronary tissue with
high-resolution for advanced plaque detection and characterization. Two large medical device companies
are currently engaged in license discussions for potential commercialization of the transducer
design/manufacturing for intravascular ultrasound (IVUS) imaging applications.
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In Vivo Bioluminescent Molecular Imaging With Application
to the Study of Secretory Clusterin, a Potential Biodosimeter
During Space Exploration
Principal Investigator: David L. Wilson, Ph.D., CWRU
Co-Investigators: David A. Boothman, Ph.D., UHCMC, CWRU
Andrew Rollins, Ph.D., CWRU
Assuring that crews can live and work safely in the ' 	 ''	 _	 X75
radiation environment of space during extended missions 	 ^'
is vital for human exploration. A key element of
maintaining astronaut health is the development of
technology to monitor the effects of space radiation on
astronauts. An In Vivo Molecular Imaging Device for
Measurement of Radiation Effects was developed for
measuring radiation exposure. The project team	 65
successfully constructed an imaging-based, biological
radiation dosimeter using a reporter to produce a specific 	 I
protein. Using this unique imaging instrument, the team	 f60
performed cellular and animal testing to show that the
bioluminescence signal responded to radiation exposure 	 s
in a predictable way. This demonstrated the potential for
future development of a new class of instruments to
measure the effects of space radiation on astronauts. 	 Figure 12.—In vivo imaging of transgenicmouse.
This imaging instrument helped gather critical
preliminary data for large infrastructure and conventional research proposals. The consortium award was
an important cornerstone for obtaining a series of successful proposals totaling more than $11 million,
which stimulated substantial growth within the CWRU imaging program. In addition, there have been
publications and research awards from NIH that were made possible with this device. The instrument was
also the first in vivo molecular imaging device for small animals demonstrated in Northeast Ohio.
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Rapid Design and Simulation Tools for Space-Bound
Biochip Devices
Principal Investigator: Arnon Chait, Ph.D., GRC
Co-Investigators: Emily Nelson, Ph.D., GRC
David Jacqmin, Ph.D., GRC
Mohammad Kassemi, Ph.D., NCSER
Charles Panzarella, Ph.D., OAI
Marianne Zlatkowski, Ph.D., CWRU
A biochip is a collection of miniaturized test sites on a surface
area usually smaller than a fingernail. The test sites, or microarrays,
can perform many biological tests at the same time. A biochip can ':. _	 MIDI	 '`
quickly perform thousands of biological reactions and are rapidly
becoming ritical for genetic, toxolo ical protein and biochemical ! r ^ ••i ^^	 , ' • 'g	 g	 g^ , P
research. Biochips could provide unique, miniaturized on board
diagnostic systems and treatment devices for long-duration NASA '•''' ' 	 =	 . .
missions. However, there are significant challenges when using ?^ " • -`^	 ' ` r
biochips in a microgravity environment. The Rapid Design and
Simulation Tools for Space-bound Biochip Devices Project • " ' -	 - •;! ^;: I• _ _
developed a numerical simulation environment for customizing and 	 ' '	 '•° :'
optimizing biochips for microgravity operations. Microgravity- 	 ::y	 Z
unique physics and biological sensing requirements were
extensively tested using leading commercial off-the-shelf simulation
codes to assess the best candidates to serve as aeneralized 	 ^_►g
simulation environment. The ACE+ code had the best combination
of embedded capabilities for the project. Customized codes were 	 n ,	 ' '^I^^I '	 ;.
developed in-house for specific microgravity physics effects
involving free surface behavior, bubble dynamics, and automated •• • • •' •	 `^
biochip optimization environment. Numerous studies encompassing
biochips and microgravity operations were completed and Figure 13.—Nanogen’s DNA/RNA
generalized tools were developed. An ACE+ based optimization 	 electrically addressable microarray.
environment for microfluidic devices was demonstrated with
follow-on work by a vendor (via SBIR funding) and is now a commercially available tool. In addition to
the collaboration among consortium members, additional partnerships were established with NASA’s
Marshall Space Flight Center, the Jet Propulsion Laboratory, Sandia National Laboratory, industry and
academic institutions.
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Controlled-Release Microsystems for Pharmacological
Agent Delivery
Principal Investigator: Shuvo Roy, Ph.D., Cleveland Clinic
Co-Investigators: Aaron Fleischman, Ph.D., Cleveland Clinic
Christian Zorman, Ph.D., CWRU
Noel Nemeth, Ph.D., GRC
David Jacqmin, Ph.D., GRC
Effectively administering pharmacological agents is a key capability needed to ensure the health of
astronauts during space missions. Miniature, implantable microsystems for the controlled release of
pharmacological agents offer the potential for both research investigations into health problems of
astronauts as well as for their immediate treatment. The unique drug delivery system investigated in this
project is based on diffusion through nanoporous membranes that are fabricated using micromechanical
systems (MEMS) techniques. Diffusion through the porous membrane is a function of pore size (5 to
100 nm in diameter), which can be designed to achieve different rates of release for a given
pharmacological agent. Continuous drug delivery through a slow infusion while maintaining the right
therapeutic concentration of the drug in the patient’s body enables better control and eliminates the need
for repeated injections. The project’s key challenges to make this highly advanced concept a reality
included ensuring structural integrity of the device, particularly fracture reliability and maintaining
predictable fluid flow characteristics. Both of these challenges were successfully addressed. The project
focused on nanoporous silicon membranes, but also explored fabrication of silicon carbide membranes.
The project established the feasibility of developing robust silicon nanoporous membranes with
appropriate pore size distribution for use in controlled release microsystems. The underlying technology
from this project has potential for use in ultra filtration applications such as generating medical grade
water and in developing a bio-artificial kidney that can be used instead of dialysis. The kidney project has
been funded through a recent NIH three-year grant to the Cleveland Clinic.
Figure 14.—Top and cross-sectional view of a nanoporous
membrane matrix.
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The Outcome
The John Glenn Biomedical Engineering Consortium projects have provided significant contributions
to NASA by developing technologies to address critical risks affecting the safety, health and performance
of astronauts during long-duration space missions. The projects have developed new diagnostic devices
and potential methods for reducing the harmful effects of exposure to space. The consortium has also
served as a pathfinder and model for interdisciplinary, multiinstitution collaboration. Additional
collaborations have resulted from the successful experiences of the consortium. The consortium has
served as a cornerstone for establishing NASA Glenn and Northeast Ohio as an integral part of NASA’s
Human Research Program.
In addition to the benefits to NASA, many of the devices and techniques investigated may improve
health care on Earth. There has been significant interest in commercializing products from several
consortium projects, potentially contributing directly to economic development in the biosciences. The
John Glenn Biomedical Engineering Consortium continues to contribute to NASA’s mission and the
vitality of Northeast Ohio.
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